ClinicalTrials.Veeva

Menu
E

Evolution Research Group | Clinical Pharmacology of Miami

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

CTP-543
Risankizumab
SSP-004184
SPD602
Isavuconazole
Tirzepatide
LY3298176
Nalbuphine
LY3502970
Mirikizumab

Parent organization

This site is a part of Evolution Research Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 213 total trials

A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)

Researchers are looking for new treatments for pain. While there are many approved treatments for pain, the treatments do not work well for everyone....

Enrolling
Pain Management
Drug: Hydrocodone/acetaminophen (HB/APAP)
Drug: Rescue Medication

The principal aim of this study is to obtain safety and tolerability data when MRT-8102 is administered orally as single and multiple doses to health...

Active, not recruiting
Healthy Volunteers
Elevated CRP
Drug: Placebo
Drug: MRT-8102

The study is to assess the safety, pharmacokinetics, and pharmacodynamic profile of HMS1005 in patient with diabetes

Enrolling
Type 2 Diabetes
Drug: HMS1005
Drug: Matching placebo

This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug kno...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: LY3537031

This is 2-part study. The primary objective of Part 1 is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy su...

Enrolling
Type 2 Diabetes
Drug: Placebo
Drug: PATAS Trifluoroacetate
New

The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.

Enrolling
Healthy Participants
Drug: NAL ER
Drug: Quinidine Sulfate

The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and ove...

Enrolling
Diabetes Mellitus, Type 1
Overweight
Drug: Tirzepatide
Drug: Acetaminophen

This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local i...

Active, not recruiting
Postoperative Pain
Drug: Saline Placebo
Drug: Liposomal Bupivacaine

This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerabilit...

Enrolling
Healthy Volunteer
Drug: Placebo
Drug: Emraclidine

The purpose of the study is to look at how the body processes a study medicine called vepdegestrant in participants with loss of liver function relat...

Enrolling
Healthy Participants
Drug: vepdegestrant

This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.

Enrolling
Hepatic Impairment
Drug: Quizartinib

The purposes of this study are to determine:* The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid...

Enrolling
Hepatic Impairment
Healthy
Drug: Mirdametinib (MEK Inhibitor)

This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, b...

Enrolling
Obesity
Drug: DA-1726
Drug: Placebo to DA-1726

A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes

Active, not recruiting
Overweight or Obese, Type 2 Diabetes
Overweight or Obese Adults
Drug: Placebo
Drug: ALV-100

Trial sponsors

Lilly logo
Shire logo
Bristol-Myers Squibb (BMS) logo
Merck Sharp & Dohme (MSD) logo
AbbVie logo
Amgen logo
Gilead Sciences logo
Bayer logo
Sanofi logo
Astellas logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems